Home / Market News / $SMMT
benzinga Corporate Catalyst Impact 75/100 ● positive

AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership

Oct 2, 2026, 1:29 PM UTC · Primary ticker $SMMT

AstraZeneca and Daiichi Sankyo are collaborating with Summit Therapeutics to test a new cancer drug combination, Datroway and ivonescimab, starting with a Phase 3 trial for triple-negative breast cancer. AstraZeneca also made a significant equity investment in Summit Therapeutics, signaling a deeper strategic commitment to ivonescimab's development across various oncology indications.

AstraZeneca and Daiichi Sankyo are entering a clinical collaboration with Summit Therapeutics to evaluate a novel cancer drug combination, Datroway and ivonescimab, beginning with a Phase 3 trial for triple-negative breast cancer. This partnership is significant as it combines established players with an emerging one, leveraging their respective drug assets and sharing trial expenses. AstraZeneca's substantial $2 billion equity investment in Summit Therapeutics underscores its long-term strategic interest in ivonescimab, not just for this specific combination but for broader oncology applications, including with other ADCs. This move could accelerate the development and market potential of ivonescimab, offering a significant upside for Summit Therapeutics and strengthening the oncology pipelines of AstraZeneca and Daiichi Sankyo. For traders, this represents a clear positive catalyst for SMMT due to the capital injection and validation, and a moderately positive signal for AZN and DSNKY as they expand their oncology reach and diversify their clinical trial risk.

$AZN positive Expanded oncology pipeline, strategic investment
$DSNKY positive Expanded oncology pipeline, co-development
$SMMT positive Major collaboration, significant equity investment, accelerated drug development
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.